Oral Semaglutide and Heart Failure Outcomes

Injected glucagon-like peptide-1 (GLP-1) receptor agonists have been shown to improve outcomes related to heart failure (HF) in individuals with HF, but whether such benefits extend to newer oral formulations is uncertain. The industry-sponsored SOUL trial previously confirmed the cardiovascular benefits of oral semaglutide in patients with type 2 diabetes plus atherosclerotic cardiovascular disease, chronic kidney disease, or both. Now, SOUL researchers have performed a secondary analysis to examine how oral semaglutide affects HF outcomes. Of nearly 10,000 enrolled patients, one fourth had a history of HF at baseline; the mean follow-up was 4 years.